Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature Working G. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–16. https://doi.org/10.1016/j.ajo.2005.03.057.

Article  PubMed  Google Scholar 

Abu El-Asrar AM, Herbort CP, Tabbara KF. Retinal vasculitis. Ocul Immunol Inflamm. 2005;13:415–33. https://doi.org/10.1080/09273940591003828.

Article  PubMed  Google Scholar 

El-Asrar AM, Herbort CP, Tabbara KF. A clinical approach to the diagnosis of retinal vasculitis. Int Ophthalmol. 2010;30:149–73. https://doi.org/10.1007/s10792-009-9301-3.

Article  PubMed  Google Scholar 

Ciardella AP, Prall FR, Borodoker N, Cunningham ET Jr. Imaging techniques for posterior uveitis. Curr Opin Ophthalmol. 2004;15:519–30. https://doi.org/10.1097/01.icu.0000144386.05116.c5.

Article  PubMed  Google Scholar 

Tugal-Tutkun I, Herbort CP, Khairallah M, Angiography Scoring for Uveitis Working G. Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol. 2010;30:539–52. https://doi.org/10.1007/s10792-008-9263-x.

Article  PubMed  Google Scholar 

Suhler EB. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123:903–12. https://doi.org/10.1001/archopht.123.7.903.

Article  CAS  PubMed  Google Scholar 

Kang HM, Lee SC. Long-term progression of retinal vasculitis in Behcet patients using a fluorescein angiography scoring system. Graefes Arch Clin Exp Ophthalmol. 2014;252:1001–8. https://doi.org/10.1007/s00417-014-2637-z.

Article  PubMed  Google Scholar 

Balci O, Jeannin B, Herbort CP Jr. Contribution of dual fluorescein and indocyanine green angiography to the appraisal of posterior involvement in birdshot retinochoroiditis and Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2018;38:527–39. https://doi.org/10.1007/s10792-017-0487-5.

Article  PubMed  Google Scholar 

Sadiq MA, Hassan M, Afridi R, Halim MS, Do DV, Sepah YJ, et al. Posterior segment inflammatory outcomes assessed using fluorescein angiography in the STOP-UVEITIS study. Int J Retin Vitreous. 2020;6:47. https://doi.org/10.1186/s40942-020-00245-w

Article  Google Scholar 

Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis. 2008;67:1656–62. https://doi.org/10.1136/ard.2007.080432.

Article  CAS  PubMed  Google Scholar 

Rosenbaum JT, Sibley CH, Lin P. Retinal vasculitis. Curr Opin Rheumatol. 2016;28:228–35. https://doi.org/10.1097/BOR.0000000000000271.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Calvo-Río V, Blanco R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, et al. Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet’s disease: a 1-year follow-up study of 124 patients. Rheumatol (Oxf). 2014;53:2223–31. https://doi.org/10.1093/rheumatology/keu266.

Article  Google Scholar 

Sharma PK, Markov GT, Bajwa A, Foster CS. Long-Term Efficacy of Systemic Infliximab in Recalcitrant Retinal Vasculitis. Retina. 2015;35:2641–6. https://doi.org/10.1097/IAE.0000000000000624.

Article  CAS  PubMed  Google Scholar 

Eser Ozturk H, Oray M, Tugal-Tutkun I. Tocilizumab for the Treatment of Behcet Uveitis that Failed Interferon Alpha and Anti-Tumor Necrosis Factor-Alpha Therapy. Ocul Immunol Inflamm. 2018;26:1005–14. https://doi.org/10.1080/09273948.2017.1355471

Article  CAS  PubMed  Google Scholar 

Atienza-Mateo B, Calvo-Rio V, Beltran E, Martinez-Costa L, Valls-Pascual E, Hernandez-Garfella M, et al. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behcet’s disease: multicentre retrospective study. Rheumatol (Oxf). 2018;57:856–64. https://doi.org/10.1093/rheumatology/kex480.

Article  CAS  Google Scholar 

Fabiani C, Sota J, Rigante D, Vitale A, Emmi G, Lopalco G, et al. Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. Clin Rheumatol. 2018;37:2805–9. https://doi.org/10.1007/s10067-018-4133-z.

Article  PubMed  Google Scholar 

Calvo-Río V, Santos-Gómez M, Calvo I, González-Fernández MI, López-Montesinos B, Mesquida M, et al. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. Arthritis Rheumatol. 2017;69:668–75. https://doi.org/10.1002/art.39940.

Article  CAS  PubMed  Google Scholar 

Muselier A, Bielefeld P, Bidot S, Vinit J, Besancenot JF, Bron A. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm. 2011;19:382–3. https://doi.org/10.3109/09273948.2011.606593.

Article  CAS  PubMed  Google Scholar 

Wennink RAW, Ayuso VK, de Vries LA, Vastert SJ, de Boer JH. Tocilizumab as an Effective Treatment Option in Children with Refractory Intermediate and Panuveitis. Ocul Immunol Inflamm. 2021;29:21–25. https://doi.org/10.1080/09273948.2020.1712431.

Article  CAS  PubMed  Google Scholar 

Ucan Gunduz G, Yalcinbayir O, Cekic S, Yildiz M, Kilic SS. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab. J Ocul Pharm Ther. 2021;37:236–40. https://doi.org/10.1089/jop.2020.0081.

Article  CAS  Google Scholar 

Santos-Gómez M, Calvo-Río V, Blanco R, Beltrán E, Mesquida M, Adán A, et al. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behcet’s disease: results of a multicentre open-label study. Clin Exp Rheumatol 2016;34:S34–S40.

PubMed  Google Scholar 

Ashkenazy N, Saboo US, Abraham A, Ronconi C, Cao JH. Successful treatment with infliximab after adalimumab failure in pediatric noninfectious uveitis. J AAPOS. 2019;23:151 e1–151 e5. https://doi.org/10.1016/j.jaapos.2019.02.006.

Article  PubMed  Google Scholar 

Maleki A, Garcia CM, Asgari S, Manhapra A, Foster CS Response to the Second TNF-alpha Inhibitor (Adalimumab or Infliximab) after Failing the First One in Refractory Idiopathic Inflammatory Retinal Vascular Leakage. Ocul Immunol Inflamm. 2021:1-10. https://doi.org/10.1080/09273948.2020.1869787.

Sepah YJ, Sadiq MA, Chu DS, Dacey M, Gallemore R, Dayani P, et al. Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis. Am J Ophthalmol. 2017;183:71–80. https://doi.org/10.1016/j.ajo.2017.08.019.

Article  CAS  PubMed  Google Scholar 

Maleki A, Manhapra A, Asgari S, Chang PY, Foster CS, Anesi SD. Tocilizumab Employment in the Treatment of Resistant Juvenile Idiopathic Arthritis Associated Uveitis. Ocul Immunol Inflamm. 2021;29:14–20. https://doi.org/10.1080/09273948.2020.1817501.

Article  CAS  PubMed  Google Scholar 

Farhat R, Clavel G, Villeneuve D, Abdelmassih Y, Sahyoun M, Gabison E, et al. Sustained Remission with Tocilizumab in Refractory Relapsing Polychondritis with Ocular Involvement: A Case Series. Ocul Immunol Inflamm. 2021;29:9–13. https://doi.org/10.1080/09273948.2020.1763405.

Article  CAS  PubMed  Google Scholar 

Adán A, Mesquida M, Llorenç V, Espinosa G, Molins B, Hernández MV, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251:2627–32. https://doi.org/10.1007/s00417-013-2436-y.

Article  CAS  PubMed  Google Scholar 

Vegas-Revenga N, Calvo-Rio V, Mesquida M, Adan A, Hernandez MV, Beltran E, et al. Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients. Am J Ophthalmol. 2019;200:85–94. https://doi.org/10.1016/j.ajo.2018.12.019.

Article  CAS  PubMed  Google Scholar 

Paul S, Zhang X. Small sample GEE estimation of regression parameters for longitudinal data. Stat Med. 2014;33:3869–81. https://doi.org/10.1002/sim.6198.

Article  PubMed  Google Scholar 

Mesquida M, Molins B, Llorenc V, Sainz de la Maza M, Adan A. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology. 2014;121:2380–6. https://doi.org/10.1016/j.ophtha.2014.06.050.

Article  PubMed  Google Scholar 

Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol. 2006;33:31–6.

CAS  PubMed  Google Scholar